prostate and testis expressed 3Genealiases: HEL-127 · PATE-DJ
Q-omics provides the consensus-scored PATE3 profile across patient tissues and cancer cell-line models. PATE3 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PATE3 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, PATE3 RNA expression shows 6,139 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight UVM, HNSC, and UCEC as cancer lineages where PATE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PATE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PATE3 survival associations across molecular data types. PATE3 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PATE3 RNA expression–survival associations across cancer types. High PATE3 expression shows unfavorable associations in UVM, LIHC, ACC, CESC and LUSC, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for PATE3 RNA expression.
This table summarizes PATE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PATE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PATE3 shows lower tumor expression in PRAD and KIRC and higher tumor expression in HNSC and BRCA. The HNSC box plot shows higher PATE3 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .028).
This table shows molecular features associated with PATE3 in patient tissues and cancer cell lines. In patient samples, PATE3 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, PATE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
